Skip to main
RXST

RxSight (RXST) Stock Forecast & Price Target

RxSight (RXST) Analyst Ratings

Based on 8 analyst ratings
Hold
Strong Buy 13%
Buy 0%
Hold 63%
Sell 25%
Strong Sell 0%

Bulls say

RxSight is a commercial-stage medical technology company focused on improving the vision of cataract surgery patients. With a strong product offering and a wide market potential, the company has the potential for impressive growth in the coming years. Despite some recent setbacks, including lower utilization and margin contraction, there are potential upside drivers such as faster LDD installed base growth and higher utilization that could lead to improved financial performance and higher share value. However, there are still risks involved in the adoption of the product, competition in the market, and the potential need for a dilutive financing round. Overall, based on their expected growth and valuation, analysts maintain a positive outlook on RxSight's stock.

Bears say

RxSight is experiencing underlying weakness in sales and utilization attributable to competitive trialing and their new collaboration with Alcon. They also face limited adoption and potential for a dilutive financing round as well as disappointing commercial execution in a market with increased competition. The fact that they have missed revenue expectations in previous quarters and consistently underperformed in terms of LDD and LAL sales also indicates a negative outlook for the company.

RxSight (RXST) has been analyzed by 8 analysts, with a consensus rating of Hold. 13% of analysts recommend a Strong Buy, 0% recommend Buy, 63% suggest Holding, 25% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RxSight (RXST) Forecast

Analysts have given RxSight (RXST) a Hold based on their latest research and market trends.

According to 8 analysts, RxSight (RXST) has a Hold consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RxSight (RXST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.